



## ResApp Health Limited Company Profile

### Overview

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation.

ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

### Speaker profile

#### Tony Keating, Chief Executive Officer & Managing Director, ResApp Health Limited



Tony Keating has over ten years' experience in commercialising technology and has led the commercialisation of ResApp's technology to date. Previously, Tony was Director, Commercial Engagement at UniQuest, one of the global leaders in commercialisation of university technology. While at UniQuest, Tony held roles as interim CEO and Non-Executive Director for a number of start-up companies.

Prior to joining UniQuest Tony held business development and engineering management roles at Exa Corporation, a US-based software company that is now listed on the NASDAQ.

For more information, please visit: [resapphealth.com.au](http://resapphealth.com.au)